ReviewInternational journal of molecular sciences2021
Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Regulatory T Cell Dysregulation in Vitiligo: A Meta-Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives.International journal of dermatology · 2025Pooled it
- Review
- Advances in Janus kinase inhibitors for vitiligo.Frontiers in immunology · 2026Review
- The role of JAK3 and TEC family kinases in vitiligo pathogenesis.Frontiers in immunology · 2026Review
- JAK Inhibitors for the Treatment of Vitiligo: Current Evidence and Emerging Therapeutic Potential.Drugs · 2025Review
- Treatment Advances in Vitiligo: An Updated Review.Dermatology practical & conceptual · 2025Review
- Lipid-based nanoparticles: advancing therapeutic strategies for vitiligo management.BioImpacts : BI · 2025Review
- Toxicities Associated with Systemic Administration of Interleukin-6 in Wistar Albino Rats.Journal of experimental pharmacology · 2025Article
- Drug-Induced Phototoxicity in Vitiligo: The Role of Hydrochlorothiazide in Photosensitivity Dermatitis.Case reports in dermatological medicine · 2025Article
- The Effect of Monobenzone Cream on Oxidative Stress and Its Relationship With Serum Levels of IL-1β and IL-18 in Vitiligo Patients.Journal of cosmetic dermatology · 2024Article
- JAK inhibitor selectivity: new opportunities, better drugs?Nature reviews. Rheumatology · 2024Review
- MYG1 drives glycolysis and colorectal cancer development through nuclear-mitochondrial collaboration.Nature communications · 2024Article
- Identification and validation of RNA-binding protein SLC3A2 regulates melanocyte ferroptosis in vitiligo by integrated analysis of single-cell and bulk RNA-sequencing.BMC genomics · 2024Article
- An Overview of the Biological Complexity of Vitiligo.Oxidative medicine and cellular longevity · 2024Review
- Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.Journal of clinical medicine · 2023Review
- The Renin-Angiotensin System: The Challenge behind Autoimmune Dermatological Diseases.Diagnostics (Basel, Switzerland) · 2023Review
- Serum Inflammatory and Oxidative Stress Markers in Patients with Vitiligo.Journal of clinical medicine · 2023Article
- Expression Signature of Immune-Related MicroRNAs in Autoimmune Skin Disease: Psoriasis and Vitiligo Insights.Molecular diagnosis & therapy · 2023Article
- Wnt Signaling Pathways: From Inflammation to Non-Melanoma Skin Cancers.International journal of molecular sciences · 2023Review
- Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a chronic autoimmune dermatosis of which the pathogenesis remains scarcely known. A wide variety of clinical studies have been proposed to investigate the immune mediators which have shown the most recurrency. However, such trials have produced controversial results. The aim of this review is to summarize the main factors involved in the pathogenesis of vitiligo, the latest findings regarding the cytokines involved and to evaluate the treatments based on the use of biological drugs in order to stop disease progression and achieve repigmentation. According to the results, the most recurrent studies dealt with inhibitors of IFN-gamma and TNF-alpha. It is possible that, given the great deal of cytokines involved in the lesion formation process of vitiligo, other biologics could be developed in the future to be used as adjuvants and/or to entirely replace the treatments that have proven to be unsatisfactory so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.